Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025

Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data.

View Full Paper
Ask AI
Bookmark
Share

Authors

LWLei WangHZHui ZhaoKYKunpeng Yang

Discussion

Loading...

Member takes

Overview

Analysis of FAERS data reveals critical docetaxel adverse events in patients, indicating personalized monitoring may enhance safety.

Key Points

  • Docetaxel treatment identified multiple adverse reactions not listed on official labels, including dehydration and leukopenia.
  • Analysis of 1,535 reports from FAERS highlighted age and gender disparities in adverse event incidences.
  • Utilizing several statistical methods like ROR and PRR, the study thoroughly assessed the safety profile of docetaxel.
  • Findings emphasize the importance of personalized risk management strategies to ensure safer docetaxel administration.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c93fe601120bef803bb076https://doi.org/10.1371/journal.pone.0331979
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Non–Small Cell Lung Cancer, Version 4.20242024 · 841 citations
  2. 2Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer2017 · 1,067 citations
  3. 3Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study2011 · 1,868 citations
  4. 4Dermatological adverse events with taxane chemotherapy2016 · 259 citations
  5. 5Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database2024 · 40 citations